On July 15, Kelun-Biotech (06990.HK) rose 10.8% in regular trading to HK$552.0, with turnover of HK$465 million.

The rally was driven by the company announcing that its core product sacituzumab tirumotecan (sac-TMT) combined with pembrolizumab achieved the primary endpoint of progression-free survival (PFS) in the Phase III OptiTROP-Lung06 study for first-line treatment of PD-L1 negative locally advanced or metastatic non-squamous NSCLC. This marks the first global Phase III study where an ADC combined with an immune checkpoint inhibitor achieved a primary endpoint in first-line treatment of driver-gene negative, PD-L1 negative non-squamous NSCLC. The study also showed an OS benefit trend, with safety consistent with prior reports and no new signals observed.

This result expands coverage beyond the previously reported PD-L1 positive population from the OptiTROP-Lung05 study presented at ASCO. The company plans to communicate with NMPA regarding regulatory next steps and currently has nine registrational studies underway in China.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)